TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Zhaoke Ophthalmology Ltd. ( (HK:6622) ) has shared an announcement.
Zhaoke Ophthalmology Ltd. announced that the National Medical Products Administration of China has accepted the New Drug Application for NVK002, a novel atropine sulphate eye drop solution for treating myopia progression in children. This development positions the company to potentially address a significant unmet need in China, where myopia is a major health concern affecting millions of children and adolescents. The acceptance of this application marks a significant step forward in the company’s efforts to establish a leading position in the market for myopia control solutions.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Ltd. is a company focused on the ophthalmology industry, specializing in innovative treatments for eye conditions. Their primary product, NVK002, is an investigational ophthalmic solution aimed at controlling myopia progression in children and adolescents, with a proprietary formulation that enhances the stability of low-concentration atropine.
Average Trading Volume: 2,715,843
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.34B
For an in-depth examination of 6622 stock, go to TipRanks’ Overview page.